Literature DB >> 11136155

Etomidate for pediatric sedation prior to fracture reduction.

R Dickinson1, A J Singer, W Carrion.   

Abstract

OBJECTIVE: While etomidate is reported as a procedural sedative in adults, its use in children has not been extensively reported. The authors describe their experience with etomidate for procedural sedation in children with extremity fractures and major joint dislocations.
METHODS: This was a retrospective descriptive chart review. The setting was a university-based emergency department (ED) that follows national guidelines for procedural sedation. Subjects were children less than 18 years old who received etomidate prior to fracture reduction or major joint dislocations. Standardized data were abstracted from the medical records, including patient demographics, diagnosis, weight, types and doses of sedative and analgesic agents used, number of boluses of etomidate, attempts at reduction, complications encountered, vitals signs before, during, and after the reduction, disposition, and the time from procedure to discharge. Descriptive statistics calculated included means and proportions with 95% confidence intervals.
RESULTS: Fifty-three children received etomidate for fracture reduction. Their mean age was 9.7; 41.5% were females. Indications for reduction included forearm fractures (38), ankle fractures (12), upper arm fractures (2), and hip dislocations (1). In most cases (83%) reduction was successful after one attempt only. The mean initial and total doses of etomidate were 0.20 mg/kg (range, 0.1 to 0.4) and 0.24 mg/kg (range, 0.13 to 0.52), respectively. Thirteen patients required a second bolus of etomidate or midazolam. Thirty-four patients (64%) were discharged from the ED after a mean observation of 94 minutes (range, 35 to 255). There were no major adverse events (95% CI = 0% to 5.7%). One patient reported nausea and one required a fluid bolus for hypotension. One patient receiving multiple sedatives and opioid analgesics was admitted for observation due to prolonged sedation. No patient required assisted ventilation or intubation.
CONCLUSIONS: These results suggest that etomidate is a safe and effective agent for procedural sedation in children requiring fracture and major joint reductions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11136155     DOI: 10.1111/j.1553-2712.2001.tb00558.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  6 in total

1.  Recognition of a Kawasaki disease shock syndrome.

Authors:  John T Kanegaye; Matthew S Wilder; Delaram Molkara; Jeffrey R Frazer; Joan Pancheri; Adriana H Tremoulet; Virginia E Watson; Brookie M Best; Jane C Burns
Journal:  Pediatrics       Date:  2009-05       Impact factor: 7.124

Review 2.  Emergency department management of pain and anxiety related to orthopedic fracture care: a guide to analgesic techniques and procedural sedation in children.

Authors:  Robert M Kennedy; Jan D Luhmann; Scott J Luhmann
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Propofol and Etomidate are Safe for Deep Sedation in the Emergency Department.

Authors:  Mark A Denny; Roger Manson; David Della-Giustina
Journal:  West J Emerg Med       Date:  2011-11

4.  Comparison of the Sedation Quality of Etomidate, Propofol, and Midazolam in Combination with Fentanyl During Phacoemulsification Cataract Surgery: A Double-Blind, Randomized, Controlled, Clinical Trial.

Authors:  Leili Adinehmehr; Hamidreza Shetabi; Darioush Moradi Farsani; Ali Salehi; Mohadese Noorbakhsh
Journal:  Anesth Pain Med       Date:  2019-04-27

Review 5.  Etomidate in pediatric anesthesiology: Where are we now?

Authors:  Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2015 Oct-Dec

Review 6.  Incidence of adverse events in paediatric procedural sedation in the emergency department: a systematic review and meta-analysis.

Authors:  M Fernanda Bellolio; Henrique A Puls; Jana L Anderson; Waqas I Gilani; M Hassan Murad; Patricia Barrionuevo; Patricia J Erwin; Zhen Wang; Erik P Hess
Journal:  BMJ Open       Date:  2016-06-15       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.